July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
The effect of long-term use of a commercial eye wash solution on the ocular surface mucin layer
Author Affiliations & Notes
  • Murat Dogru
    Ophthalmology, Keio University, Tokyo, Japan
    Ophthalmology, Tsurumi University, Japan
  • Naoyuki Kozuki
    Ophthalmology, Tsurumi University, Japan
  • Miho Tanaka
    Research and Drug Development, Kobayashi Pharmaceuticals, Japan
  • Ayako Shibasaki
    Ophthalmology, Tsurumi University, Japan
  • Hiroko Yano
    Research and Drug Development, Kobayashi Pharmaceuticals, Japan
  • Hiroshi Fujishima
    Ophthalmology, Tsurumi University, Japan
  • Footnotes
    Commercial Relationships   Murat Dogru, Kobayashi Pharmaceuticals (F); Naoyuki Kozuki, Kobayashi Pharmaceuticals (R); Miho Tanaka, Kobayashi Pharmaceuticals (E); Ayako Shibasaki, Kobayashi Pharmaceuticals (R); Hiroko Yano, Kobayashi Pharmaceuticals Research and Drug Development (E); Hiroshi Fujishima, Kobayashi Pharmaceuticals (C), Kobayashi Pharmaceuticals (F)
  • Footnotes
    Support  Kobayashi International Scholarship Foundation
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4699. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Murat Dogru, Naoyuki Kozuki, Miho Tanaka, Ayako Shibasaki, Hiroko Yano, Hiroshi Fujishima; The effect of long-term use of a commercial eye wash solution on the ocular surface mucin layer. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4699.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : In this study, we investigated the corneal safety and ocular surface mucin changes after one month use of a preservative free commercial eye wash solution.

Methods : Forty-six healthy eyes of 23 individuals (19 males,4 females; mean age:35.4±7.5 yrs) without ocular allergies, dry eyes, or other ocular diseases were recruited in this prospective study. A commercial eye wash solution(EyebonRw,Kobayashi Pharmaceuticals,Osaka,Japan)was used for eye wash. Conjunctival impression cytology (IC) was performed before and one month after wash b.i.d.mRNA was extracted from the IC papers and Real-time PCR was done for the mRNA expressions of MUC5AC and MUC16. Cytology imprints also underwent immunohistochemistry for MUC16. The area of staining was calculated with a digital software (WINROOF 2018, Mitani Shoji Ltd, Fukui, Japan) and the ratios with the area of epithelial cells were calculated. Periodic Acid Schiff staining was done for goblet cell density calculations. Dry eye symptom questionnaire and tear film break up time (BUT) examinations were performed.Biomicroscopy was performed for corneal staining(min score:0 point, maximum score:9 points). IRB was obtained. ANOVA was used for statistical analyses. A p value less than 5% was statistically significant.

Results : No significant differences in MUC5AC and MUC16 mRNA expressions between washed and unwashed eyes after one month(p>0.05)were seen.No significant differences were observed in BUT values (Eye wash group; pre-wash BUT: 8.3±3.5sec, post-wash BUT: 8.0±2.3;Non wash group: pre-wash BUT: 8.1±2.1sec, post-wash BUT: 8.0±2.2) corneal fluorescein staining scores and DEQS scores before and one month after eye wash (Eye wash group; pre-wash DEQS: 14.8±9.4 pts, post-wash DEQS: 5.6±6.3; non wash group: pre-wash DEQS: 14.8±9.4, post-wash DEQS: 8.9±11.1) and in comparison to unwashed contralateral eyes (p>0.05). The ratios of the areas stained with MUC16 antibodies to the areas of conjunctival epithetial cells did not show significant differences before and after eye wash (p>0.05). Goblet cell densities also showed no significant differences before and after eye wash (p>0.05).

Conclusions : The results of the current study suggest that one month use of a non-preserved commercial eye wash solution had no detrimental effects on the tear film and the ocular surface mucins suggesting their safety on the ocular surface.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.